Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Multi-centric, Open-labeled, Phase-IV Study to Assess Safety and Efficacy of LYFAQUIN™ (Centhaquine Citrate) as a Resuscitative Agent for Hypovolemic Shock to be Used as an Adjuvant to Standard Treatment of Shock

NCT05956418 is registered in ClinicalTrials.gov with Pharmazz, Inc. as lead sponsor.

NCT NCT05956418
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05956418 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Multi-centric, Open-labeled, Phase-IV Study to Assess Safety and Efficacy of LYFAQUIN™ (Centhaquine Citrate) as a Resuscitative Agent for Hypovolemic Shock to be Used as an Adjuvant to Standard Treatment of Shock
Lead sponsor
Pharmazz, Inc.
Phase
Phase 4
Overall status
Recruiting
Start date
August 13, 2021
Completion date
February 28, 2027
Enrollment
400 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

hypovolemic shock